Autoimmune hepatitis (AIH) is a chronic liver condition where the immune system attacks healthy liver cells, causing inflammation and potential scarring. Whilst AIH itself does not directly cause fatty liver disease, patients with this autoimmune condition may develop fat accumulation in the liver through shared metabolic risk factors or as a consequence of corticosteroid treatment. Understanding the relationship between autoimmune hepatitis and fatty liver disease is essential for appropriate management, as each condition requires specific therapeutic approaches. This article explores how these conditions may coexist, their symptoms, diagnosis, and evidence-based treatment options available through the NHS.

Understanding Autoimmune Hepatitis and Fatty Liver Disease

Autoimmune hepatitis (AIH) is a chronic inflammatory liver condition in which the body's immune system mistakenly attacks healthy liver cells, causing progressive inflammation and potential scarring (fibrosis). This condition affects approximately 10–20 people per 100,000 in the UK and can occur at any age, though it is more common in women. Whilst autoimmune hepatitis is characterised by immune-mediated liver inflammation, it is important to understand that there is no proven direct autoimmune mechanism that causes fatty liver disease (hepatic steatosis) as a primary manifestation of AIH.

Fatty liver disease, or hepatic steatosis, refers to the abnormal accumulation of fat within liver cells. This can occur in two main forms: non-alcoholic fatty liver disease (NAFLD)—also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD)—which is associated with metabolic factors such as obesity and type 2 diabetes, and alcoholic fatty liver disease, related to excessive alcohol consumption. When fatty liver occurs alongside autoimmune hepatitis, it typically represents a coexisting condition rather than a direct consequence of the autoimmune process.

Patients with autoimmune hepatitis may develop fatty liver through shared metabolic risk factors, including obesity, type 2 diabetes, and dyslipidaemia, or as a consequence of corticosteroid treatment used to manage the autoimmune condition. Corticosteroids, which are first-line therapy for autoimmune hepatitis, can promote weight gain and insulin resistance, potentially contributing to fat accumulation in the liver. Understanding the distinction between these two conditions is essential for appropriate management, as each requires specific therapeutic approaches whilst addressing any overlapping risk factors.

How Autoimmune Conditions Lead to Liver Fat Accumulation

The relationship between autoimmune hepatitis and fatty liver disease is complex and multifactorial rather than directly causal. Autoimmune hepatitis causes liver damage through a different mechanism than fatty liver disease. In AIH, autoreactive T-lymphocytes target liver cells (hepatocytes), triggering chronic inflammation mediated by cytokines. This inflammatory process can lead to hepatocyte injury, fibrosis, and eventually cirrhosis if left untreated.

Fatty liver accumulation in patients with autoimmune hepatitis typically occurs through indirect mechanisms. The most significant contributor is often immunosuppressive therapy, particularly corticosteroids such as prednisolone. These medications, whilst essential for controlling the autoimmune inflammation, can induce metabolic changes including increased appetite, weight gain, insulin resistance, and altered lipid metabolism—all of which promote hepatic fat deposition. Long-term corticosteroid therapy is associated with an increased risk of metabolic syndrome, though the exact prevalence varies depending on dose, duration, and individual patient factors.

Additionally, patients with autoimmune hepatitis may have coexisting metabolic risk factors independent of their autoimmune condition. These include obesity, type 2 diabetes, dyslipidaemia, and sedentary lifestyle—the same factors that drive non-alcoholic fatty liver disease in the general population. Some research indicates that chronic inflammation itself, regardless of cause, may contribute to insulin resistance and metabolic dysfunction, potentially creating a permissive environment for fat accumulation.

It is also worth noting that certain overlap syndromes exist, such as autoimmune hepatitis with features of primary biliary cholangitis, which may present with different metabolic profiles. However, there remains no established direct autoimmune mechanism that specifically causes fatty liver disease as a primary manifestation.

Recognising Symptoms of Autoimmune-Related Fatty Liver

Early-stage fatty liver disease is often asymptomatic, whether occurring alone or alongside autoimmune hepatitis. Many patients are diagnosed incidentally through abnormal liver function tests or imaging performed for other reasons. However, when symptoms do occur, they may reflect either the autoimmune hepatitis, the fatty liver component, or both conditions simultaneously.

Symptoms of autoimmune hepatitis can include persistent fatigue (often the most prominent complaint), jaundice (yellowing of skin and eyes), abdominal discomfort particularly in the right upper quadrant, dark urine, pale stools, itching (pruritus, more typical of cholestatic liver disease but may occur), joint pain, and skin rashes. Some patients experience acute presentations with severe fatigue and jaundice, whilst others have an insidious onset with vague symptoms over months or years. Women may notice menstrual irregularities, and some patients develop features of other autoimmune conditions such as thyroid disease or inflammatory bowel disease.

Fatty liver disease itself rarely causes specific symptoms until advanced stages. When present, symptoms may include a sensation of fullness or discomfort in the right upper abdomen, generalised fatigue, and occasionally malaise. As fatty liver progresses to non-alcoholic steatohepatitis (NASH) with inflammation and fibrosis, symptoms may become more pronounced.

When both conditions coexist, distinguishing which is causing symptoms can be challenging. Patients should be alert to warning signs requiring urgent medical attention. Call 999 or go to A&E immediately if you experience vomiting blood, black tarry stools, new confusion or drowsiness, or severe jaundice with abdominal swelling. These may indicate advanced liver disease or acute decompensation. For other new or worsening symptoms, contact your GP or call NHS 111 for advice.

Diagnosis and Testing for Autoimmune Liver Conditions

Diagnosing autoimmune hepatitis requires a combination of clinical assessment, blood tests, imaging, and often liver biopsy. Initial investigations typically include liver function tests (LFTs), which may show elevated transaminases (ALT and AST), often with ALT equal to or higher than AST. Alkaline phosphatase (ALP) and bilirubin may also be raised, particularly in more severe disease.

Autoimmune serology is essential for diagnosis. Key tests include antinuclear antibodies (ANA), anti-smooth muscle antibodies (SMA), and anti-liver kidney microsomal antibodies (anti-LKM1). Elevated serum immunoglobulin G (IgG) levels are characteristic of autoimmune hepatitis. In atypical or seronegative cases, additional antibodies such as anti-SLA/LP may be tested. According to British Society of Gastroenterology (BSG) guidance on the management of abnormal liver blood tests, patients with suspected autoimmune liver disease should be referred to specialist hepatology services for comprehensive assessment.

Identifying fatty liver typically involves imaging studies. Ultrasound scanning is often the first-line investigation and can detect moderate to severe hepatic steatosis, appearing as increased echogenicity (brightness) of the liver. However, ultrasound has limited sensitivity for mild fat accumulation. More advanced imaging such as MRI-based techniques (MRI-PDFF) or controlled attenuation parameter (CAP) measured during transient elastography (FibroScan) can quantify liver fat more accurately.

Assessing liver fibrosis in patients with NAFLD follows the NICE NG49 pathway: initial non-invasive assessment using the FIB-4 score or NAFLD Fibrosis Score; if results are indeterminate or suggest advanced fibrosis, proceed to the Enhanced Liver Fibrosis (ELF) blood test or transient elastography (FibroScan) to stage fibrosis severity and guide specialist referral.

Liver biopsy remains the gold standard for definitive diagnosis, particularly when autoimmune hepatitis is suspected. Histological examination can confirm interface hepatitis (characteristic of AIH), assess the degree of inflammation and fibrosis, and identify coexisting steatosis. The biopsy helps distinguish autoimmune hepatitis from other liver conditions and can reveal the extent of any fatty change.

Additional investigations may include viral hepatitis screening (hepatitis B and C), assessment for metabolic syndrome components (fasting glucose, lipid profile, HbA1c), and exclusion of other causes of liver disease such as haemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency.

Treatment Options for Autoimmune Hepatitis with Fatty Liver

Management of autoimmune hepatitis centres on immunosuppression to control the autoimmune inflammatory process. First-line therapy typically consists of corticosteroids, usually prednisolone, often combined with azathioprine as a steroid-sparing agent. The standard regimen involves high-dose prednisolone initially (30–40 mg daily), gradually tapered as liver inflammation improves, with azathioprine (1–2 mg/kg daily) introduced early to maintain remission whilst minimising corticosteroid exposure.

Before starting azathioprine, thiopurine methyltransferase (TPMT) activity should be measured, as deficiency increases the risk of severe bone marrow suppression. The MHRA also advises considering testing for NUDT15 gene variants, which are associated with increased risk of myelosuppression. Regular monitoring of full blood count and liver function is essential throughout treatment. Most patients require long-term maintenance therapy, and treatment withdrawal is only considered after sustained biochemical and histological remission, typically after at least two years.

For patients who cannot tolerate azathioprine or fail to achieve remission, alternative immunosuppressants include mycophenolate mofetil, ciclosporin, or tacrolimus. Budesonide (a corticosteroid with high first-pass hepatic metabolism and potentially fewer systemic side effects) may be considered in selected non-cirrhotic patients as an off-label treatment, though evidence remains limited. Budesonide should not be used in patients with cirrhosis or acute severe autoimmune hepatitis.

Managing coexisting fatty liver disease requires addressing metabolic risk factors. There are currently no licensed pharmacological treatments specifically for NAFLD in the UK, so management focuses primarily on lifestyle modification. However, this presents a challenge when patients are receiving corticosteroids for autoimmune hepatitis, as these medications promote weight gain and metabolic dysfunction.

Strategies to minimise fatty liver progression include using the lowest effective corticosteroid dose, optimising the steroid-sparing regimen with azathioprine or alternatives, and intensive lifestyle intervention. According to NICE NG49, pioglitazone may be considered (off-label) for adults with biopsy-proven NASH after discussing the risks and benefits, whether or not they have type 2 diabetes. Vitamin E (off-label) may be considered in non-diabetic adults with biopsy-proven NASH where appropriate. GLP-1 receptor agonists are not licensed for NAFLD or NASH and should only be used for their approved indications (type 2 diabetes or obesity management), not solely for liver disease.

Long-term immunosuppression and corticosteroid therapy require additional preventive measures. Patients should receive vaccinations including annual influenza, pneumococcal, and hepatitis A and B vaccines as appropriate. Bone health should be monitored with DXA scanning, and calcium and vitamin D supplementation should be considered, with bisphosphonates if indicated, to prevent osteoporosis.

Regular monitoring is essential for patients with both conditions, including periodic liver function tests, assessment of disease activity, surveillance for complications, and screening for hepatocellular carcinoma in those with cirrhosis (six-monthly ultrasound, with or without alpha-fetoprotein, as per NICE NG50 and BSG guidance).

Report any suspected side effects from your medications via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for Yellow Card in the Google Play or Apple App Store. Seek medical advice promptly if you develop signs of infection, unusual bruising or bleeding, or other concerning symptoms.

Managing Your Condition: NHS Support and Lifestyle Changes

NHS support for autoimmune hepatitis typically involves shared care between specialist hepatology services and your GP. Following diagnosis, you should be under the care of a consultant hepatologist with expertise in autoimmune liver disease. Regular outpatient appointments allow monitoring of disease activity, medication adjustment, and screening for complications. Many NHS trusts have specialist hepatology nurses who provide invaluable support, education, and a point of contact between appointments.

Your GP plays a crucial role in ongoing management, including prescribing maintenance medications, monitoring blood tests, managing side effects of immunosuppression, and coordinating care with other specialists. Ensure your GP receives comprehensive discharge summaries from hepatology appointments and understands your treatment plan. Some areas have enhanced care pathways allowing GPs to manage stable patients with specialist support.

Lifestyle modifications are fundamental to managing both autoimmune hepatitis and fatty liver disease. Weight management is particularly important if you have coexisting fatty liver. According to NICE NG49, aim for gradual, sustainable weight loss of 0.5–1 kg per week if overweight, targeting 7–10% body weight reduction, which has been shown to improve liver fat and inflammation. This can be challenging when taking corticosteroids, so consider referral to NHS dietetic services for personalised advice.

Dietary recommendations include following a balanced, Mediterranean-style diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats whilst limiting processed foods, refined carbohydrates, and saturated fats. Alcohol should be avoided completely or limited to minimal levels, as it can exacerbate both autoimmune hepatitis and fatty liver disease. The UK Chief Medical Officers' low-risk drinking guidelines recommend no more than 14 units per week, spread over three or more days. However, many hepatologists recommend complete abstinence in patients with active liver disease; discuss your individual situation with your hepatology team.

Regular physical activity is essential—aim for at least 150 minutes of moderate-intensity exercise weekly, such as brisk walking, cycling, or swimming. Exercise improves insulin sensitivity, aids weight management, and directly reduces liver fat independent of weight loss. Start gradually if you have significant fatigue, and discuss appropriate activity levels with your healthcare team.

Women of childbearing potential should discuss pregnancy planning and contraception with their hepatology team, as some medications used for autoimmune hepatitis require careful management or adjustment before and during pregnancy. Early discussion with both hepatology and obstetric services is essential.

Patient support organisations such as the British Liver Trust provide excellent resources, including information leaflets, online forums, and local support groups where you can connect with others managing similar conditions. They offer a helpline (0800 652 7330) staffed by specialist nurses who can answer questions and provide support.

Medication adherence is crucial—take immunosuppressants exactly as prescribed, even when feeling well, as stopping treatment can trigger disease flares. Attend all monitoring appointments and blood tests. Report any new symptoms, infections, or concerns promptly. If you experience side effects from medications, discuss these with your healthcare team rather than stopping treatment independently. With appropriate management, most patients with autoimmune hepatitis achieve good disease control and maintain quality of life whilst addressing coexisting metabolic liver disease through comprehensive lifestyle measures.

Frequently Asked Questions